The role of technetium-99m-labeled octreotide acetate scintigraphy in suspected breast cancer and correlates with expression of SSTR

Nuclear Medicine and Biology

Volumn 35, Issue 6, 2008, Pages 665-671

  Wang, Feng ^a   Wang, Zizheng ^a   Wu, Jie ^a   Qu, Wei ^a   Yao, Weixuan ^a   Zhao, Jianhua ^a   Liu, Zijun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; mRNA; Scintigraphy; Somatostatin receptor

Indexed keywords

MESSENGER RNA; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; OCTREOTIDE TC 99M; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST ADENOCARCINOMA; BREAST CARCINOMA; CANCER DIAGNOSIS; CORRELATION ANALYSIS; DRUG UPTAKE; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTION AND FORECASTING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCINTIMAMMOGRAPHY; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; OCTREOTIDE; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 48349135901     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.04.010     Document Type: Article

References (31)

1. Parkin D.M., Pisani P., and Ferlay J. Global cancer statistics CA. Cancer J Clin 49 (1999) 33-64
2. Greenlee R.T., Murray T., and Bolden S. Cancer statistics, 2000 CA. Cancer J Clin 50 (2000) 7-33
3. Zhang S.-W., Chen W.-Q., Kong L.-Z., et al. An analysis of cancer incidence and mortality from 30 cancer registries in China, 1998-2002. Bull Chin Cancer 15 7 (2005) 430-448
4. Pisano E.D., Fajardio L.L., Caudry D.J., et al. Fine-needle aspiration biopsy of nonpalpable lesions in a multicenter clinical trial: results from the Radiologic Diagnostic Oncology Group V. Radiology 219 (2001) 785-792
5. Sauer T., Myrvold K., Lomo J., et al. Fine-needle aspiration cytology in nonpalpable mammographic abnormalities in breast cancer screening. Breast 12 (2003) 314-319
6. Jackman R.J., Burbank F., Parker S.H., et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology 218 (2001) 497-502
7. Lind P., Gallowitsch H., Kogler D., et al. Tc-99m tetrofosmin mammoscintigraphy: a prospective study in primary breast lesions. Nucl Med 35 (1996) 225-229
8. Spanu A., Farris A., Schillaci O., et al. The usefulness of Tc-99m tetrofosmin scintigraphy in patients with breast cancer recurrences. Nucl Med Commun 24 (2003) 145-154
9. Flanagan F., Dehdashti F., and Siegel B. PET in breast cancer. Semin Nucl Med 28 (1998) 290-302
10. Avril N., Schelling M., Dose J., Weber W., and Schwaiger M. Utility of PET in breast cancer. Clin Positron Imag 2 (1999) 261-271
11. Bombardieri E., and Grippa F. PET imaging in breast cancer. J Nucl Med 43 (2001) 245-256
12. Czernin J. FDG PET in breast cancer: a different view of its clinical use. Mol Imag Biol 4 (2002) 35-45
13. Heinisch M., Gallowitsch H., Mikosch P., et al. Comparison of FDG PET and dynamic contrast enhanced MRI in the evaluation of suggestive breast lesions. Breast 12 (2003) 17-22
14. Vikic-Topic S., Raisch K.P., Kvols L.K., et al. Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin Endocrinol Metab 80 (1995) 2974-2979
15. Schulz S., Helmholz T., Schmitt J., et al. True positive somatostatin receptor scintigraphy in primary breast cancer correlates with expression of sst2A and sst5. Breast Cancer Res Treat 72 (2002) 221-226
16. Reubi J.C., Waser B., Schaer J.C., et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28 (2001) 836-846
17. van Eijck C.H., Krenning E.P., Bootsma A., et al. Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 343 (1994) 640-643
18. Kwekkeboom D.J., and Krenning E.P. Somatostatin receptor imaging. Semin Nucl Med 32 (2002) 84-91
19. Mezi S, Primi F, Orsi E, et al. Somatostatin Scintigraphy in the metastatic breast cancer patients. Oncol Rep 2005;13:31-35.
20. de Jong M., Kwekkeboom D., Valkema R., et al. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 30 (2003) 463-469
21. de Jong M., Valkema R., Jamar F., et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 32 (2002) 133-140
22. Breeman W.A., Mearadji A., Capello A., et al. Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3] octreotate in a rat liver micrometastases model. Int J Cancer 104 (2003) 376-379
23. Waldherr C., Pless M., Maecke H.R., et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med 43 (2002) 610-616
24. Waldherr C., Pless M., Maecke H.R., Haldemann A., and Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 12 (2001) 941-945
25. 18F-FDG dual head coincidense imaging. J Nucl Med 48 (2007) 1442-1448
26. Sharma K., and Srikant C.B. Induction of wild-type p53 Bax and acidic endonuclease during somatostatin signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer 76 (1998) 259-266
27. Papotti M., Kumar U., Volante M., et al. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol 54 (2001) 641-649
28. Van Den Bossche B., Van Belle S., De Wintery F., et al. Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scintigraphy. J Nucl Med 47 (2006) 6-13
29. Pettinato C., Sarnelli A., Di Donna M., et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 51 (2008) 72-79
30. Antunes P., Ginj M.H., Zhang B., et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?. Eur J Nucl Med Mol Imaging 34 (2007) 982-993
31. Wild D., Schmitt J.S., Ginj M., et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labeling with various radiometals. Eur J Nucl Med Mol Imaging 30 (2003) 1338-1347